Literature DB >> 11605614

A cost comparison of heart transplantation versus alternative operations for cardiomyopathy.

J T Cope1, A K Kaza, C C Reade, K S Shockey, J A Kern, C G Tribble, I L Kron.   

Abstract

BACKGROUND: Heart transplantation is an established therapy for cardiomyopathy but is limited by organ shortage and expense. As a result, alternative operations have been proposed including coronary bypass, mitral valve repair, and left ventricular reconstruction. Because it is unknown whether alternative operations are less expensive than replacing the diseased heart, we compared in-hospital costs and early outcome of these operations with elective heart transplantation.
METHODS: We compared clinical and financial data of 268 patients with ejection fraction less than 30% who underwent elective heart transplantation (n = 52, UNOS status 2 only), coronary bypass (n = 176), mitral repair (n = 15), or left ventricular reconstruction (n = 25). Data were evaluated for between-group differences, with p less than 0.05 as significant.
RESULTS: Preoperative ejection fraction, although similar for heart transplantation (21.2% +/- 1.3%), coronary bypass (25.8% +/- 0.4%), mitral repair (22.9% +/- 1.5%), and left ventricular reconstruction (24.2% +/- 2.1%), was significantly different between the former two (p < 0.001). There was no difference in operative mortality: 5.8% (3 of 52), 3.4% (7 of 176), 6.7% (1 of 15), and 4.0% (1 of 25), respectively (p = 0.8). However, total hospital cost of heart transplantation was significantly greater than all others: $75,992 +/- $5,380, $25,008 +/- $1,446, $32,375 +/- $2,379, and $26,584 +/- $4,076, respectively (p < 0.001). Organ procurement expenses alone comprised 39.7% ($30,169) of total transplant cost. Kaplan-Meier survival analysis failed to show any survival difference between the various groups (p = 0.86)
CONCLUSIONS: Compared with heart transplantation, alternative operations yield a comparable early outcome and long-term survival, and are markedly less expensive. The cost of transplantation, which is largely due to procurement expenses, is yet another reason to attempt alternative operations for cardiomyopathy whenever feasible.

Entities:  

Mesh:

Year:  2001        PMID: 11605614     DOI: 10.1016/s0003-4975(01)02997-6

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  [Surgery in terminal mitral valve disease].

Authors:  M Bauer; M Pasic; R Hetzer
Journal:  Z Kardiol       Date:  2001-12

2.  Ventricular reconstruction results in improved left ventricular function and amelioration of mitral insufficiency.

Authors:  Aditya K Kaza; Mayank R Patel; Steven M Fiser; Stewart M Long; John A Kern; Curtis G Tribble; Irving L Kron
Journal:  Ann Surg       Date:  2002-06       Impact factor: 12.969

Review 3.  Surgical ventricular restoration and other surgical approaches to heart failure.

Authors:  Patrick I McConnell; Robert E Michler
Journal:  Curr Heart Fail Rep       Date:  2004 Apr-May

4.  The Cost of Heart Transplant in Iran: A Multicenter Analysis.

Authors:  Z H Ahmadi; Sh Shafaghi; M H Mandegar; M Salehi; B Sharif Kashani; F Naghashzadeh; A Jahangirifard; A Bakhshandeh; A Afshar; M Kazempour; F Sheikhan
Journal:  Int J Organ Transplant Med       Date:  2021

Review 5.  Nontransplant surgical options for congestive heart failure.

Authors:  J Ferrão de Oliveira; Manuel J Antunes
Journal:  Curr Cardiol Rep       Date:  2004-05       Impact factor: 2.931

6.  Cost analysis of 163 consecutive heart transplant operationsin an Indian setting.

Authors:  Komarakshi Balakrishnan; Coimbatore Nageswaran
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2020-08-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.